Revenues

9 Months Ended

Sep. 30, 2019

Revenue From Contract With Customer [Abstract]

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019		2018
OraQuick®	$	13,256		$	12,016	$	37,813	$	40,813
Oragene®		11,590			22,450		27,316		52,799
ORAcollect®		2,489			1,353		9,032		3,460
Intercept®		2,230			1,743		6,144		5,811
Histofreezer® (through August 16, 2019)		569			2,199		5,718		6,526
Other products		5,165			3,689		14,875		11,177
Net product revenues		35,299			43,450		100,898		120,586

Royalty income		758			1,132		2,956		4,827
Research and development funding		(183	)		1,083		679		4,540
Charitable support reimbursement		85			220		203		1,544
Grant funding		30			-		201		-
Other revenues		690			2,435		4,039		10,911
Net revenues	$	35,989		$	45,885	$	104,937	$	131,497

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	26,245	$	36,883	$	74,712	$	99,860
Europe		2,767		1,982		8,188		7,187
Other regions		6,977		7,020		22,037		24,450
	$	35,989	$	45,885	$	104,937	$	131,497

Customer and Vendor Concentrations. One of our customers accounted for 24% of our accounts receivable as of September 30, 2019. The same customer accounted for approximately 17% and 11% of our net consolidated revenues for the three and nine months ended September 30, 2019 and 39% and 27% of our net consolidated revenues for the three and nine months ended September 30, 2018.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its product. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2019 and December 31, 2018 includes customer prepayments of $2,150 and $2,057, respectively. Deferred revenue as of September 30, 2019 and December 31, 2018 also includes $ 1,790 and $1,464, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.